HHS proposing stripping Title X funding from clinics providing, referring abortions

A proposed regulation from HHS would prevent any healthcare organizations which provides abortions or make referrals for patients to receive abortions from being getting federal family planning funds in a program known as Title X.

As NPR reports, Title X provides $260 million for reproductive health services. Direct federal funding for abortions has been prohibited by Congress for decades, but conservative lawmakers have sought to deny all federal funding to groups like Planned Parenthood for having any involvement in abortion services.

Under President Ronald Reagan, a similar rule was proposed but never fully implemented, before being rescinded years later under President Bill Clinton.

Before the rule was even proposed, HHS had been sued by Planned Parenthood and other groups, arguing it goes against what Congress intended in creating Title X.

"This 'gag rule' is not only unconscionable, but it undermines medical ethics by forcing health care professionals to withhold accurate and timely medical information from patients," Jenn Conti, MD, a fellow with Physicians for Reproductive Health, said in a statement.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.